Health Care · Electromedical & Electrotherapeutic Apparatus

OM Outset Medical, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 148461295 filings
Russell 2000

OM at a glance

Outset Medical, Inc. (OM, SEC CIK 1484612) filed its latest 10-K annual report on February 13, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and Form 4 insider filings as recently as November 17, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Outset Medical, Inc. (OM) reported revenue of $119.5 million (up 5.1% from FY2024) and a net loss of $81.7 million. Diluted EPS was -$5.37.
  • As of December 31, 2024, 11 institutional investment managers tracked by SignalX reported holding Outset Medical, Inc. (OM) shares worth $10.3 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Gaeta Renee on November 16, 2026 of 4,498 shares at $3.67 per share.
  • In the last 90 days, OM insiders reported 2 open-market purchases ($870K) and 2 open-market sales ($29K) on Form 4, a net purchase of $841K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$119.5M
+5.1% vs prior year
Insiders · 90 days
2 buys · 2 sells
Net +$841K
13F holders
11 funds
$10.3M
Latest 8-K
Nov 4, 2026
Item 2.02

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • No new products, services, or segments introduced or emphasized this year
  • No strategic shift or changed competitive positioning disclosed in this filing
  • Independent registered public accounting firm named as KPMG LLP, Auditor ID: 185
  • Business section mainly references governance codes and proxy statement disclosures for fiscal 2026

Risk Factors

  • FDA warning letter in 2023 and ongoing compliance risks with medical device regulations impacting Tablo production and approval processes
  • Dependence on Mexico manufacturing exposed to U.S. tariffs risk from Section 232 Trade Expansion Act investigation started September 2025
  • Reliance on third-party suppliers and insourced Mexican manufacturing with potential supply chain disruption from labor disputes or public health crises
  • Competition from dominant home dialysis providers DaVita and Fresenius challenging Tablo's market penetration in home and post-acute care
  • Revenue concentrated in Tablo product with customer financial pressures from rising interest rates and budget constraints elongating sales cycles since 2023

Management Discussion & Analysis

  • Revenue $119.5M, up 5% YoY from $113.7M; product revenue $84.8M (+5%), service revenue $34.7M (+6%)
  • Gross margin 39.1% vs 33.9%, gross profit $46.8M, up 21%, driven by higher console and consumable margins
  • Best segment: Consumables revenue up $2.9M, console revenue up $0.9M; worst: overall sales down from 2023, console sales portion declined
  • Operating expenses down 25% to $113.5M from $151.9M, driven by cuts in R&D (-45%), sales and marketing (-22%), general and admin (-13%)
  • No explicit cash flow, buyback or dividend data disclosed; noted cost reduction and efficiency efforts ongoing
  • Forward outlook risks: macroeconomic pressure, tariffs, rising costs, cautious customer capital spending delaying sales; focus on expanding acute and home dialysis markets

AI summary of the OM 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Quarterly revenue $33.6M, up 14% YoY from $29.4M, driven by product revenue up 15% to $23.7M
  • Gross margin 40.7% vs 39.4% YoY, with service and other revenue up 12% to $9.9M
  • Operating loss $12.3M vs $15.8M YoY, net loss $14.7M vs $17.8M
  • Cash, restricted cash and short-term investments $140.7M; nine-month operating cash outflow $32.9M
  • Near-term losses expected; customer purchase deferrals, tariffs, policy uncertainty and cautious capital spending remain headwinds

Risk Factors

  • New FDA Form 483 triggered by Q3 2026 San Jose inspection, citing CAPA, complaint handling, change documentation and data analysis
  • Regulatory compliance risk: unresolved FDA observations could bring further communications or official action
  • Operational risk: supplier noncompliance could disrupt timely production and required product quantities
  • Product risk: unanticipated adverse events could trigger labeling changes, restrictions or recalls
  • Financial risk: continued FDA remediation costs and management time may be significant

AI summary of the OM 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 4, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 earnings announcement for quarter ended September 30, 2026
  • Press release furnished as Exhibit 99.1, containing financial results and management commentary

Item EX-99.1: Item EX-99.1

  • Q3 revenue $33.6M, up 14% YoY and 6% sequentially, supporting continued commercial momentum
  • Console revenue $10.5M, up 26% YoY, while recurring revenue reached $23.1M, up 10%
Filed Aug 28, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • General Counsel John Brottem departing effective September 11, 2026
  • Departure attributed to pursuing other professional opportunities
Filed Aug 6, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Q2 revenue $31.6M, up 1% YoY and 14% sequentially, indicating modest growth acceleration
  • Gross margin expanded to 42.0% from 37.8%; service margin surged to 32.6% from 6.9%

Item 2.02: Results of Operations and Financial Condition

  • Q2 2026 earnings announcement covering the quarter ended June 30, 2026
  • Press release issued August 6, 2026, with financial results in Exhibit 99.1

AI summaries of OM 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for OM

Don't miss the next OM filing

  • Alerts as it files. A push when OM files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut OM, by share count.
  • Ask anything. An AI agent that reads every OM filing and answers with sources.

OM alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Gaeta ReneeSellNov 16, 2026$3.67
Trigg LeslieSellNov 16, 2026$3.67
Leonard Braden MichaelBuyOct 2, 2026$3.88
Leonard Braden MichaelBuyOct 1, 2026$3.53
Brottem John L.SellAug 17, 2026$4.39
Trigg LeslieSellAug 17, 2026$4.39
Gaeta ReneeSellAug 17, 2026$4.39
Gaeta ReneeAJun 26, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue$130.4M$113.7M$119.5M
Gross Profit-$38.6M$46.8M
Operating Income--$113.4M-$66.7M
Net Income--$128.0M-$81.7M
Gross Margin-33.9%39.1%
Op. Margin--99.7%-55.8%
Net Margin--112.6%-68.3%
Balance Sheet
Total Assets$313.8M$275.8M$264.5M
Equity-$26.8M$127.0M
ROE--477.2%-64.3%
Per Share
EPS-$-2.46$-5.37
Cash Flow
Operating CF--$116.3M-$46.3M
CapEx-$912K$798K

Source: XBRL data in Outset Medical, Inc. (OM)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q4 2024

Aggregate OM share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
OM shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q4 202411$10.3M

Source: 13F-HR filings on SEC EDGAR (aggregated from 11 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

OM filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 17, 2026--
4Nov 17, 2026--
10-QNov 4, 2026Analysis
8-KNov 4, 2026Analysis-
4Oct 5, 2026--
8-KAug 28, 2026Analysis-
4Aug 18, 2026--
4Aug 18, 2026--
4Aug 18, 2026--
SC 13GAug 12, 2026-
10-QAug 6, 2026Analysis
8-KAug 6, 2026Analysis-
4Jun 29, 2026--
4Jun 29, 2026--
4Jun 29, 2026--
8-KJun 17, 2026Analysis-
4Jun 5, 2026-
4Jun 5, 2026-
4Jun 5, 2026-
4Jun 5, 2026-
4Jun 5, 2026-
4Jun 5, 2026-
8-KJun 5, 2026Analysis
4Jun 5, 2026-
8-KMay 29, 2026Analysis

Related Health Care companies

All Health Care →

OM SEC filings: frequently asked questions

Are OM insiders buying or selling?

In the last 90 days, Outset Medical, Inc. (OM) officers, directors and 10% owners reported 2 open-market purchases worth $870,260 by 1 insider and 2 open-market sales worth $28,997 by 2 insiders on Form 4, a net purchase of $841,264. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold OM stock?

As of December 31, 2024, the largest Outset Medical, Inc. (OM) holders among the 13F filers tracked by SignalX were FMR LLC (Fidelity) ($4.1 million), Vanguard Group Inc ($2.9 million), Millennium Management ($1.5 million), Renaissance Technologies LLC ($762,000), Two Sigma Investments ($542,000). 13F-HR reports are filed up to 45 days after each quarter ends.

What was OM's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Outset Medical, Inc. (OM) reported revenue of $119.5 million (up 5.1% from FY2024) and a net loss of $81.7 million. Diluted EPS was -$5.37. The figures come from the XBRL data in the 10-K.

What are the main risks in OM's latest 10-K?

In the 10-K filed February 13, 2026, Outset Medical, Inc. (OM) flagged: FDA warning letter in 2023 and ongoing compliance risks with medical device regulations impacting Tablo production and approval processes. Dependence on Mexico manufacturing exposed to U.S. tariffs risk from Section 232 Trade Expansion Act investigation started September 2025. (AI summary of the Risk Factors section.)

What did OM report in its latest 8-K?

Outset Medical, Inc. (OM) filed an 8-K on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 earnings announcement for quarter ended September 30, 2026.

What are the latest OM SEC filings?

Outset Medical, Inc. (OM) filed its latest 10-K annual report on February 13, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and a Form 4 insider filing on November 17, 2026.

What is OM's SEC CIK number?

Outset Medical, Inc. (OM)'s SEC Central Index Key (CIK) is 1484612. EDGAR lists every OM filing under that number.

Ask anything about OM

The research agent reads OM's filings, financials, insider trades and 13F holders, then answers with sources.